<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30223117</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1768-3254</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>158</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>European journal of medicinal chemistry</Title>                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.</ArticleTitle>            <Pagination>                <MedlinePgn>286-301</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(18)30788-8</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2018.09.016</ELocationID>            <Abstract>                <AbstractText>The enzyme inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes an essential step in the de novo biosynthesis of guanine nucleotides, and thus regulates the guanine nucleotide pool required for cell proliferation. Of the two isoforms, human IMPDH type 2 (hIMPDH2) is a validated molecular target for potential immunosuppressive, antiviral and anticancer chemotherapy. In search of newer hIMPDH2 inhibitors as potential anticancer agents, three novel series (A: 5-aminoisobenzofuran-1(3H)-one, B: 3,4-dimethoxyaniline and C: benzo[d]-[1,3]dioxol-5-ylmethanamine) were synthesized and evaluated for in vitro and cell-based activities. A total of 37 molecules (29-65) were screened for their in vitro hIMPDH2 inhibition, with particular emphasis on establishing their structure-activity relationship (SAR) trends. Eight compounds (hits, 30, 31, 33-35, 37, 41 and 43) demonstrated significant enzyme inhibition (&gt;70% @ 10 μM); especially the A series molecules were more potent than B series (&lt;70% inhibition @ 10 μM), while C series members were found to be inactive. The hIMPDH2 IC<sub>50</sub> values for the hits ranged from 0.36 to 7.38 μM. The hits displaying &gt;80% hIMPDH2 inhibition (30, 33, 35, 41 and 43) were further assessed for their cytotoxic activity against cancer cell lines such as MDA-MB-231 (breast adenocarcinoma), DU145 (prostate carcinoma), U87 MG (glioblastoma astrocytoma) and a normal cell line, NIH-3T3 (mouse embryonic fibroblast) using MTT assay. Most of the compounds exhibited higher cellular potency against cancer cell lines and notably lower toxicity towards NIH-3T3 cells compared to mycophenolic acid (MPA), a prototypical hIMPDH2 inhibitor. Two of the series A hits (30 and 35) were evaluated in human peripheral blood mononuclear cells (hPBMC) assay and found to be better tolerated than MPA. The calculated/predicted molecular and physicochemical properties were satisfactory with reference to drug-likeness. The molecular docking studies clearly demonstrated crucial interactions of the hits with the cofactor-binding site of hIMPDH2, further providing critical information for refining the design strategy. The present study reports the design and discovery of structurally novel hIMPDH2 inhibitors as potential anticancer agents and provides a guide for further research on the development of safe and effective anticancer agents, especially against glioblastoma.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shah</LastName>                    <ForeName>Chetan P</ForeName>                    <Initials>CP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Chemistry, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (West), Mumbai, 400 056, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kharkar</LastName>                    <ForeName>Prashant S</ForeName>                    <Initials>PS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pharmaceutical Chemistry, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (West), Mumbai, 400 056, India. Electronic address: Prashant.Kharkar@nmims.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Eur J Med Chem</MedlineTA>            <NlmUniqueID>0420510</NlmUniqueID>            <ISSNLinking>0223-5234</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D001555">Benzene Derivatives</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 1.1.1.205</RegistryNumber>                <NameOfSubstance UI="D007168">IMP Dehydrogenase</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001555" MajorTopicYN="N">Benzene Derivatives</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007168" MajorTopicYN="N">IMP Dehydrogenase</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D041681" MajorTopicYN="N">NIH 3T3 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">5-Aminoisobenzofuran-1(3H)-one</Keyword>            <Keyword MajorTopicYN="N">Anticancer agents</Keyword>            <Keyword MajorTopicYN="N">IMPDH</Keyword>            <Keyword MajorTopicYN="N">MTT assay</Keyword>            <Keyword MajorTopicYN="N">hIMPDH2 inhibitors</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30223117</ArticleId>            <ArticleId IdType="pii">S0223-5234(18)30788-8</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejmech.2018.09.016</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>